Harnessing Immunity to Eliminate Cancer & Chronic Viral Disease
Pinion Immunotherapeutics is a Maryland-based biotechnology company focused on developing novel immunotherapies for chronic viral infections and virus-driven cancers. Its proprietary AI-driven mRNA platform generates immunotherapies targeting HPV-related precancer, AML, EBV, and HSV, designed to activate CD8+ T cells while inducing virus-neutralizing antibodies to achieve durable immune control.
INVESTOR CONTACTPinion's Strategic Advantage
AI-Driven Discovery
Proprietary antigen selection optimized for MHC binding, T cell induction, and neutralizing antibody response.
mRNA + LNP Delivery
Engineered LNP for enhanced lymph node trafficking, APC uptake, and superior MHC-I loading vs. protein vaccines.
Dual Immune Activation
Simultaneous induction of CD8+ cytotoxic T lymphocytes and virus-neutralizing antibodies for maximum efficacy.
De-risked by Prior Data
Each program supported by prior Phase 1-3 clinical evidence informing antigen selection and proof-of-concept.
Pinion Immunotherapeutics is Built for Capital Efficiency and Scientific Excellence
Pinion operates as a lean, high-impact fully integrated company, deploying capital directly to science and clinical trials, not overhead. Our in-house Rockville lab and animal facility take every program from concept to in vivo data under one roof, without dependence on external CROs. Our leadership team brings deep expertise across mRNA platform development, FDA regulatory strategy, clinical trial design, and immunology.
Our programs target indications with large addressable populations, no curative standard of care, and high economic burden, where mRNA immunotherapy offers a genuine path to functional cure.
Development Pipeline
Colorectal Cancer